Table 2

Correlation coefficients between FoH screener scores, respondent characteristics and patient-reported outcomes (HFS-II, GAD-7, PHQ-8)

Total score (rt)Worry subscale (rw)Behavior subscale (rb)
Age (years)−0.09*−0.08*−0.07
Duration of T1D (years)−0.17*−0.17*−0.11*
Number of comorbidities0.19*0.17*0.18*
MDI versus pump−0.08−0.05−0.11*
Glucometer use (vs CGM use)
Self-reported A1c (%)0.21*0.15*0.27*
Gold score0.12*0.13*0.03
Number of mild hypoglycemia per week−0.02−0.02−0.01
Number of moderate hypoglycemia per week0.010.02−0.02
Number of severe hypoglycemia in the past 12 months0.09*0.080.07
Number of lifetime severe hypoglycemia0.080.09*0.03
BMI (kg/m2)0.09*0.060.13*
Comfortable blood glucose range—low0.15*0.12*0.16*
Comfortable blood glucose range—high0.050.000.15*
FoH worry score0.95*
FoH behavior score0.74*0.49*
General anxiety (GAD-7)0.37*0.32*0.33*
Depression (PHQ-8)0.37*0.31*0.35*
HFS total score0.78*0.72*0.61*
HFS worry score0.74*0.75*0.45*
HFS behavior score0.65*0.52*0.69*
  • Gold score measures impaired awareness of hypoglycemia (responses range from ‘Always aware (1)’ to ‘Never aware (7)’). GAD-7 is a 7-item anxiety scale developed to diagnose generalized anxiety disorder. PHQ-8 is an outcome measure that is used both as a diagnostic and severity measure for depressive disorders in clinical studies. HFS-II (short form) is an 11-item patient-reported outcome measure that assesses adults’ behavior (5 items) and worry (6 items) related to hypoglycemia in the past 6 months.

  • *P<0.05.

  • A1c, glycated hemoglobin; BMI, body mass index; CGM, continuous glucose monitoring; FoH, fear of hypoglycemia; GAD-7, 7-Item Generalized Anxiety Disorder Scale; HFS-II, Hypoglycemia Fear Survey-II; MDI, multiple daily injections; PHQ-8, 8-Item Patient Health Questionnaire; rb, correlation coefficient behavior score; rt, correlation coefficient total score; rw, correlation coefficient worry score; T1D, type 1 diabetes.